Australia's Novogen reports clinical promise on candidate to kill cancer stem cells

Novogen's ($NVGN) CEO says one of the Australian company's drugs has shown promise in pretrial as a way to kill cancer stem cells, particularly those involved in primary and secondary brain cancers. Graham Kelly said the candidate currently called TRXE-009 was first tested in Australian trials against brain cells. It was found to be effective in patients who could not respond to temozolomide, the standard chemotherapy for that type of cancer. Report